CA1040271A - Cellule beta artificielle - Google Patents

Cellule beta artificielle

Info

Publication number: CA1040271A
Authority: CA; Canada
Prior art keywords: blood; blood glucose; glucose concentration; rate; means adapted
Prior art date: 1975-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA218,410A

Other languages

English (en)

Inventor

Anthony M. Albisser

Bernard S. Leibel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hospital for Sick Children HSC

Original Assignee

Hospital for Sick Children HSC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-01-22

Filing date

1975-01-22

Publication date

1978-10-10

1975-01-22 Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC

1975-01-22 Priority to CA218,410A priority Critical patent/CA1040271A/fr

1976-01-13 Priority to GB1264/76A priority patent/GB1498332A/en

1976-01-15 Priority to AU10324/76A priority patent/AU1032476A/en

1976-01-19 Priority to FR7601294A priority patent/FR2298832A1/fr

1976-01-20 Priority to IT47701/76A priority patent/IT1053386B/it

1976-01-20 Priority to DE19762601893 priority patent/DE2601893A1/de

1976-01-21 Priority to SE7600588A priority patent/SE7600588L/xx

1976-01-22 Priority to JP51006345A priority patent/JPS51125993A/ja

1978-10-10 Application granted granted Critical

1978-10-10 Publication of CA1040271A publication Critical patent/CA1040271A/fr

1979-02-12 Priority to US06/011,601 priority patent/US4245634A/en

Status Expired legal-status Critical Current

Links

210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title claims abstract description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 132
239000008280 blood Substances 0.000 claims abstract description 130
210000004369 blood Anatomy 0.000 claims abstract description 130
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 125
239000008103 glucose Substances 0.000 claims abstract description 112
102000004877 Insulin Human genes 0.000 claims abstract description 67
108090001061 Insulin Proteins 0.000 claims abstract description 67
229940125396 insulin Drugs 0.000 claims abstract description 66
238000001802 infusion Methods 0.000 claims abstract description 36
230000008859 change Effects 0.000 claims abstract description 21
206010012601 diabetes mellitus Diseases 0.000 claims description 18
238000004458 analytical method Methods 0.000 claims description 5
230000002572 peristaltic effect Effects 0.000 claims description 4
230000000541 pulsatile effect Effects 0.000 claims description 3
230000003345 hyperglycaemic effect Effects 0.000 claims 5
230000009977 dual effect Effects 0.000 claims 2
238000012360 testing method Methods 0.000 description 15
241000282472 Canis lupus familiaris Species 0.000 description 14
239000008121 dextrose Substances 0.000 description 13
208000013016 Hypoglycemia Diseases 0.000 description 8
238000013459 approach Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 7
230000033228 biological regulation Effects 0.000 description 6
230000001276 controlling effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000000034 method Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
238000012935 Averaging Methods 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
235000013305 food Nutrition 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
239000002933 immunoreactive insulin Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
201000004569 Blindness Diseases 0.000 description 1
241000928610 Coula Species 0.000 description 1
240000003550 Eusideroxylon zwageri Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
206010023379 Ketoacidosis Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
229940123958 Short-acting insulin Drugs 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
HFCYZXMHUIHAQI-UHFFFAOYSA-N Thidiazuron Chemical compound C=1C=CC=CC=1NC(=O)NC1=CN=NS1 HFCYZXMHUIHAQI-UHFFFAOYSA-N 0.000 description 1
235000004251 balanced diet Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Optics & Photonics (AREA)
Surgery (AREA)
Medical Informatics (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Hematology (AREA)
External Artificial Organs (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA218,410A 1975-01-22 1975-01-22 Cellule beta artificielle Expired CA1040271A (fr)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
CA218,410A CA1040271A (fr)	1975-01-22	1975-01-22	Cellule beta artificielle
GB1264/76A GB1498332A (en)	1975-01-22	1976-01-13	Artificial beta cell and computer programmed therefor
AU10324/76A AU1032476A (en)	1975-01-22	1976-01-15	Artificial beta cell
FR7601294A FR2298832A1 (fr)	1975-01-22	1976-01-19	Procede de regulation de
IT47701/76A IT1053386B (it)	1975-01-22	1976-01-20	Cellula beta artificiale con calcolatore e relativo procedimento di applicazione
DE19762601893 DE2601893A1 (de)	1975-01-22	1976-01-20	Verfahren und vorrichtung zur regelung der blutzuckerkonzentration von diabetikern
SE7600588A SE7600588L (sv)	1975-01-22	1976-01-21	Sett att reglera blodglykoskocentrationer i blod, artificiell betacell samt dator for anvendning i en sadan
JP51006345A JPS51125993A (en)	1975-01-22	1976-01-22	Artificial beta cell
US06/011,601 US4245634A (en)	1975-01-22	1979-02-12	Artificial beta cell

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA218,410A CA1040271A (fr)	1975-01-22	1975-01-22	Cellule beta artificielle

Publications (1)

Publication Number	Publication Date
CA1040271A true CA1040271A (fr)	1978-10-10

Family

ID=4102116

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA218,410A Expired CA1040271A (fr)	1975-01-22	1975-01-22	Cellule beta artificielle

Country Status (8)

Country	Link
JP (1)	JPS51125993A (fr)
AU (1)	AU1032476A (fr)
CA (1)	CA1040271A (fr)
DE (1)	DE2601893A1 (fr)
FR (1)	FR2298832A1 (fr)
GB (1)	GB1498332A (fr)
IT (1)	IT1053386B (fr)
SE (1)	SE7600588L (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0095291A3 (en) *	1982-05-15	1984-03-21	Kabushiki Kaisha Kyoto Daiichi Kagaku	Continuous measurement of the concentration of a predetermined ingredient in a diluted liquid
WO1990001697A1 (fr) *	1988-08-05	1990-02-22	Red Kite Technology Limited	Controle de la glycemie
WO2003006091A1 (fr) *	2001-07-11	2003-01-23	The University Of Western Australia	Appareil de perfusion pour reguler le taux de glycemie et procedes correspondant
US7509156B2 (en)	2005-05-18	2009-03-24	Clarian Health Partners, Inc.	System for managing glucose levels in patients with diabetes or hyperglycemia
US11857763B2 (en)	2016-01-14	2024-01-02	Insulet Corporation	Adjusting insulin delivery rates
US11865299B2 (en)	2008-08-20	2024-01-09	Insulet Corporation	Infusion pump systems and methods
US11929158B2 (en)	2016-01-13	2024-03-12	Insulet Corporation	User interface for diabetes management system
USD1020794S1 (en)	2018-04-02	2024-04-02	Bigfoot Biomedical, Inc.	Medication delivery device with icons
USD1024090S1 (en)	2019-01-09	2024-04-23	Bigfoot Biomedical, Inc.	Display screen or portion thereof with graphical user interface associated with insulin delivery
US11969579B2 (en)	2017-01-13	2024-04-30	Insulet Corporation	Insulin delivery methods, systems and devices
US12042630B2 (en)	2017-01-13	2024-07-23	Insulet Corporation	System and method for adjusting insulin delivery
US12064591B2 (en)	2013-07-19	2024-08-20	Insulet Corporation	Infusion pump system and method
US12076160B2 (en)	2016-12-12	2024-09-03	Insulet Corporation	Alarms and alerts for medication delivery devices and systems
US12106837B2 (en)	2016-01-14	2024-10-01	Insulet Corporation	Occlusion resolution in medication delivery devices, systems, and methods
US12318577B2 (en)	2017-01-13	2025-06-03	Insulet Corporation	System and method for adjusting insulin delivery
US12343502B2 (en)	2017-01-13	2025-07-01	Insulet Corporation	System and method for adjusting insulin delivery
US12383166B2 (en)	2016-05-23	2025-08-12	Insulet Corporation	Insulin delivery system and methods with risk-based set points
US12485223B2 (en)	2017-01-13	2025-12-02	Insulet Corporation	Controlling insulin delivery
US12551621B2 (en)	2017-01-13	2026-02-17	Insulet Corporation	System and method for adjusting insulin delivery
US12562251B1 (en)	2018-05-09	2026-02-24	Bigfoot Biomedical, Inc.	Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4370983A (en) *	1971-01-20	1983-02-01	Lichtenstein Eric Stefan	Computer-control medical care system
DE2737922A1 (de) *	1977-08-23	1979-03-08	Fresenius Chem Pharm Ind	Kuenstliche endokrine druese
US4151845A (en) *	1977-11-25	1979-05-01	Miles Laboratories, Inc.	Blood glucose control apparatus
US4469681A (en) *	1979-07-31	1984-09-04	The Rockefeller University	Method and system for the controlled release of biologically active substances to a body fluid
US4348387A (en) *	1979-07-31	1982-09-07	The Rockefeller University	Method and system for the controlled release of biologically active substances to a body fluid
JPS598969A (ja) *	1982-07-09	1984-01-18	藤沢薬品工業株式会社	人工膵臓
FR2531333B1 (fr) *	1982-08-09	1986-04-04	Centre Nat Rech Scient	Pancreas bio-artificiel a ultrafiltration
DD230730A3 (de) *	1984-01-02	1985-12-11	Zentralinstitut Fuer Diabetes	Einrichtung zur prospektiven automatischen bestimmung individualspezifischer glukoseregulationsparameter
CA1254091A (fr) *	1984-09-28	1989-05-16	Vladimir Feingold	Systeme implantable pour la perfusion de medicaments
DE3545260A1 (de) *	1985-12-20	1987-06-25	Juergen Schrezenmeir	Vorrichtung zur kontinuierlichen oder diskontinuierlichen verabreichung von insulin in den menschlichen koerper
US7037277B1 (en)	1998-07-21	2006-05-02	Spectrx, Inc.	System and method for fluid management in a continuous fluid collection and sensor device
US7384396B2 (en)	1998-07-21	2008-06-10	Spectrx Inc.	System and method for continuous analyte monitoring
US8417311B2 (en)	2008-09-12	2013-04-09	Optiscan Biomedical Corporation	Fluid component analysis system and method for glucose monitoring and control
CA2702116C (fr)	2007-10-10	2021-01-05	Optiscan Biomedical Corporation	Systeme d'analyse de composant de fluide et procede pour controler et reguler le glucose
GB2523989B (en)	2014-01-30	2020-07-29	Insulet Netherlands B V	Therapeutic product delivery system and method of pairing
CN111905188B (zh)	2015-02-18	2022-07-22	英赛罗公司	流体输送和输注装置及其使用方法
US10765807B2 (en)	2016-09-23	2020-09-08	Insulet Corporation	Fluid delivery device with sensor
US11565043B2 (en)	2018-05-04	2023-01-31	Insulet Corporation	Safety constraints for a control algorithm based drug delivery system
AU2019347755B2 (en)	2018-09-28	2023-02-02	Insulet Corporation	Activity mode for artificial pancreas system
EP3864668A1 (fr)	2018-10-11	2021-08-18	Insulet Corporation	Détection d'événement pour système d'administration de médicament
US11801344B2 (en)	2019-09-13	2023-10-31	Insulet Corporation	Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en)	2019-09-27	2024-03-19	Insulet Corporation	Onboarding and total daily insulin adaptivity
EP4069082B1 (fr)	2019-12-06	2024-06-05	Insulet Corporation	Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète
US11833329B2 (en)	2019-12-20	2023-12-05	Insulet Corporation	Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
JP7512395B2 (ja)	2020-01-06	2024-07-08	インスレットコーポレイション	持続する残差に基づく食事および／または運動行為の予測
EP4100958A1 (fr)	2020-02-03	2022-12-14	Insulet Corporation	Utilisation d'une logique floue pour prédire un comportement d'utilisateur affectant la glycémie
US11551802B2 (en)	2020-02-11	2023-01-10	Insulet Corporation	Early meal detection and calorie intake detection
US11547800B2 (en)	2020-02-12	2023-01-10	Insulet Corporation	User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11986630B2 (en)	2020-02-12	2024-05-21	Insulet Corporation	Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en)	2020-02-14	2022-05-10	Insulet Corporation	Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US12495994B2 (en)	2020-02-20	2025-12-16	Insulet Corporation	Meal bolus subcategories in model based insulin therapy
US11607493B2 (en)	2020-04-06	2023-03-21	Insulet Corporation	Initial total daily insulin setting for user onboarding
US12121700B2 (en)	2020-07-22	2024-10-22	Insulet Corporation	Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en)	2020-07-31	2023-06-27	Insulet Corporation	Techniques to reduce risk of occlusions in drug delivery systems
US12569619B2 (en)	2020-09-21	2026-03-10	Insulet Corporation	Techniques for determining automated insulin delivery dosages
EP4696344A3 (fr)	2020-09-30	2026-04-15	Insulet Corporation	Dispositif d'administration de médicament à glucomètre optique intégré
US12115351B2 (en)	2020-09-30	2024-10-15	Insulet Corporation	Secure wireless communications between a glucose monitor and other devices
US11160925B1 (en)	2021-01-29	2021-11-02	Insulet Corporation	Automatic drug delivery system for delivery of a GLP-1 therapeutic
US11904140B2 (en)	2021-03-10	2024-02-20	Insulet Corporation	Adaptable asymmetric medicament cost component in a control system for medicament delivery
EP4305636A1 (fr)	2021-03-10	2024-01-17	Insulet Corporation	Dispositif d'administration de médicament ayant une composante de coût de niveau d'analyte réglable et par segments pour répondre aux écarts de niveau d'analyte positifs persistants
US12592306B2 (en)	2021-04-28	2026-03-31	Insulet Corporation	Devices and methods for initialization of drug delivery devices using measured analyte sensor information
US12496398B2 (en)	2021-05-28	2025-12-16	Insulet Corporation	Threshold based automatic glucose control response
EP4101482A1 (fr)	2021-06-07	2022-12-14	Insulet Corporation	Prédiction de sécurité d'exercice basée sur les conditions physiologiques
US12514980B2 (en)	2021-06-30	2026-01-06	Insulet Corporation	Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase
US12521486B2 (en)	2021-07-16	2026-01-13	Insulet Corporation	Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems
WO2023049900A1 (fr)	2021-09-27	2023-03-30	Insulet Corporation	Techniques permettant l'adaptation de paramètres dans des systèmes d'aide par entrée d'utilisateur
US11439754B1 (en)	2021-12-01	2022-09-13	Insulet Corporation	Optimizing embedded formulations for drug delivery
EP4243030A1 (fr)	2022-03-09	2023-09-13	Insulet Corporation	Ajustement de paramètres d'administration de médicament dans un mode d'administration de médicament en boucle ouverte
EP4646726A1 (fr)	2023-01-06	2025-11-12	Insulet Corporation	Administration de bolus de repas lancée automatiquement ou manuellement avec assouplissement automatique ultérieur des contraintes de sécurité

1975
- 1975-01-22 CA CA218,410A patent/CA1040271A/fr not_active Expired
1976
- 1976-01-13 GB GB1264/76A patent/GB1498332A/en not_active Expired
- 1976-01-15 AU AU10324/76A patent/AU1032476A/en not_active Expired
- 1976-01-19 FR FR7601294A patent/FR2298832A1/fr not_active Withdrawn
- 1976-01-20 IT IT47701/76A patent/IT1053386B/it active
- 1976-01-20 DE DE19762601893 patent/DE2601893A1/de active Pending
- 1976-01-21 SE SE7600588A patent/SE7600588L/xx unknown
- 1976-01-22 JP JP51006345A patent/JPS51125993A/ja active Pending

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0095291A3 (en) *	1982-05-15	1984-03-21	Kabushiki Kaisha Kyoto Daiichi Kagaku	Continuous measurement of the concentration of a predetermined ingredient in a diluted liquid
WO1990001697A1 (fr) *	1988-08-05	1990-02-22	Red Kite Technology Limited	Controle de la glycemie
WO2003006091A1 (fr) *	2001-07-11	2003-01-23	The University Of Western Australia	Appareil de perfusion pour reguler le taux de glycemie et procedes correspondant
US7509156B2 (en)	2005-05-18	2009-03-24	Clarian Health Partners, Inc.	System for managing glucose levels in patients with diabetes or hyperglycemia
US11865299B2 (en)	2008-08-20	2024-01-09	Insulet Corporation	Infusion pump systems and methods
US12296139B2 (en)	2008-08-20	2025-05-13	Insulet Corporation	Infusion pump systems and methods
US12064591B2 (en)	2013-07-19	2024-08-20	Insulet Corporation	Infusion pump system and method
US11929158B2 (en)	2016-01-13	2024-03-12	Insulet Corporation	User interface for diabetes management system
US12303667B2 (en)	2016-01-14	2025-05-20	Insulet Corporation	Adjusting insulin delivery rates
US12106837B2 (en)	2016-01-14	2024-10-01	Insulet Corporation	Occlusion resolution in medication delivery devices, systems, and methods
US12303668B2 (en)	2016-01-14	2025-05-20	Insulet Corporation	Adjusting insulin delivery rates
US11857763B2 (en)	2016-01-14	2024-01-02	Insulet Corporation	Adjusting insulin delivery rates
US12383166B2 (en)	2016-05-23	2025-08-12	Insulet Corporation	Insulin delivery system and methods with risk-based set points
US12076160B2 (en)	2016-12-12	2024-09-03	Insulet Corporation	Alarms and alerts for medication delivery devices and systems
US11969579B2 (en)	2017-01-13	2024-04-30	Insulet Corporation	Insulin delivery methods, systems and devices
US12318577B2 (en)	2017-01-13	2025-06-03	Insulet Corporation	System and method for adjusting insulin delivery
US12343502B2 (en)	2017-01-13	2025-07-01	Insulet Corporation	System and method for adjusting insulin delivery
US12042630B2 (en)	2017-01-13	2024-07-23	Insulet Corporation	System and method for adjusting insulin delivery
US12485223B2 (en)	2017-01-13	2025-12-02	Insulet Corporation	Controlling insulin delivery
US12551621B2 (en)	2017-01-13	2026-02-17	Insulet Corporation	System and method for adjusting insulin delivery
USD1020794S1 (en)	2018-04-02	2024-04-02	Bigfoot Biomedical, Inc.	Medication delivery device with icons
US12562251B1 (en)	2018-05-09	2026-02-24	Bigfoot Biomedical, Inc.	Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices
USD1024090S1 (en)	2019-01-09	2024-04-23	Bigfoot Biomedical, Inc.	Display screen or portion thereof with graphical user interface associated with insulin delivery

Also Published As

Publication number	Publication date
JPS51125993A (en)	1976-11-02
IT1053386B (it)	1981-08-31
DE2601893A1 (de)	1976-07-29
SE7600588L (sv)	1976-07-23
FR2298832A1 (fr)	1976-08-20
AU1032476A (en)	1977-07-21
GB1498332A (en)	1978-01-18

Publication	Publication Date	Title
CA1040271A (fr)	1978-10-10	Cellule beta artificielle
US4245634A (en)	1981-01-20	Artificial beta cell
Albisser et al.	1974	Clinical control of diabetes by the artificial pancreas
Albisser et al.	1974	An artificial endocrine pancreas
US7402153B2 (en)	2008-07-22	Closed-loop method for controlling insulin infusion
Mirouze et al.	1977	Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes
Christiansen et al.	1982	Kidney function and size in diabetics before and during initial insulin treatment
CA1121243A (fr)	1982-04-06	Appareil pour regler la glycemie
Sulli et al.	2003	Continuous Subcutaneous Insulin Infusion in Children and Adolescents with Diabetes Mellitus: Decreased HbA 1c with Low Risk of Hypoglycemia.
US7267665B2 (en)	2007-09-11	Closed loop system for controlling insulin infusion
Shichiri et al.	1979	Normalization of the paradoxic secretion of glucagon in diabetics who were controlled by the artificial beta cell
Raskin et al.	1979	Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps
US20080188796A1 (en)	2008-08-07	Closed-Loop Method for Controlling Insulin Infusion
Wiseman et al.	1984	Threshold effect of plasma glucose in the glomerular hyperfiltration of diabetes
Service et al.	1980	Characteristics of glycemic stability
Albisser	2005	Devices for the control of diabetes mellitus
EP1382363A1 (fr)	2004-01-21	Systéme en boucle fermée de gestion pour contrôler les niveaux de taux de glucose sanguin
Schiffrin et al.	1984	Intensified insulin therapy in the type I diabetic adolescent: a controlled trial
GB1574267A (en)	1980-09-03	Apparatus for controlling a quantity of insulin infusion
Meyer et al.	1979	Diabetic management by insulin infusion during major surgery
Rønn et al.	1987	Evaluation of insulin pump treatment under routine conditions
Freckmann et al.	2001	Recent advances in continuous glucose monitoring
Sherwin et al.	1980	Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump
Clarke et al.	1977	Clinical evaluation and preliminary studies on the use of an artificial pancreatic beta cell in juvenile diabetes mellitus
Horwitz et al.	1980	Hyperinsulinism complicating control of diabetes mellitus by an artificial beta-cell